Hans-Peter Gerber
Vermögen: 324 298 $ am 30.06.2026
Vermögen: 324 298 $ am 30.06.2026
Hans-Peter Gerber currently works at T-CURX GmbH, as Chairman and Sutro Biopharma, Inc., as Chief Scientific Officer from 2023.
Dr. Gerber also formerly worked at NBE-Therapeutics AG, as Independent Director from 2017 to 2021 and Maverick Therapeutics, Inc., as President, Director & Chief Science Officer from 2016 to 2018.
Dr. Gerber received his graduate degree and doctorate degree from the University of Zurich.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC. 0,06 % | 31.03.2026 | 9.768 ( 0,06 % ) | 324 298 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.09.2023 |
T-CURX GmbH
T-CURX GmbH BiotechnologyHealth Technology Operates as a biotech company that develops immunotherapies to treat cancer | Vorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Direktor/Vorstandsmitglied | 01.01.2021 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Operates as a preclinical stage biotech company which develops T cell redirecting antibody therapeutics | Präsident | 01.01.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Sutro Biopharma, Inc.
Sutro Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops new products in protein vaccines and therapeutics | Health Technology |
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NBE-Therapeutics AG
NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Operates as a preclinical stage biotech company which develops T cell redirecting antibody therapeutics | Health Technology |
T-CURX GmbH
T-CURX GmbH BiotechnologyHealth Technology Operates as a biotech company that develops immunotherapies to treat cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen